Orionis Biosciences, a privately held, clinical‑stage life sciences company focused on discovery, design and development of precision medicines, has appointed Dr. Giulio Draetta, M.D., Ph.D., as Chief Strategy Officer. Draetta joins Orionis as the company advances and broadens its portfolio across molecular glues, conditionally active cytokines, immune cell engager therapeutic modalities and multiple next‑generation technology platforms. “Giulio is a renowned, world-class scientist and bio...